திசையன் கண்டுபிடிப்பு நிதி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Home / Analysis / Covid-driven biotech and healthcare run set to continue for investors with high risk tolerance Covid-driven biotech and healthcare run set to continue for investors with high risk tolerance Schroder Global Healthcare and Axa Framlinton Health Care have returned 519% and 289% over the past decade The biotech and healthcare sectors have flourished during the pandemic as companies raced to develop a Covid-19 vaccine. Those already invested have reaped the rewards, but what next? Is it time to reconsider this exposure or is there more to come? Data from Grand View Research forecasts the biotech market to grow from $752.88bn in 2020 to $2.44trn by 2028. Similarly, genomics is expected to reach $62.9bn by 2028 driven by healthcare innovation and tailoring care to an individual patient, while providing more data on diseases and human genetics.

Ailsa craigSouth ayrshireUnited kingdomJames yardleyJenny turtonPaul stannardDavid pinnigerJohn bowlerBb healthcareDowning fourBiotech growthView researchAxa framlington health careVector innovation fundWorldwide healthcareSv health managers international biotechnology